Pal Miheller

Pal Miheller

Auto-generated profile, based on publicly available information

Pal Miheller

Department of Surgery, Transplantation and Gastroenterology, Faculty of Medicine Semmelweis University Budapest Hungary

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2021 in Life
Verified
Journal Article
Open access
PDF file
ÉPÉva Piros
Éva Piros
Ákos SzabóÁkos Szabó
Ákos Szabó
FRFanni Rencz
Fanni Rencz
VBValentin Brodszky
Valentin Brodszky
NWNorbert M Wikonkál
Norbert M Wikonkál
Péter HollóPéter Holló
Péter Holló
BACKGROUND: Psoriasis is frequently accompanied by metabolic syndrome. Effect of anti-tumor necrosis factor therapies on increases in body weight is well-known. Data on the effects of interleukin-17 inhibitors are limited. Authors determined the effect of anti-interleukin-17 therapies on the body composition and serum lipid and inflammatory parameters among severe psoriatic patients. METHODS: Thirty-five severe psoriatic patients were enrolled. Twenty-two received secukinumab and 13 received ixekizumab as their 2nd-or 3rd-line biological treatment. Before treatment initiation and 6 months later, laboratory examinations measuring metabolic and inflammatory panels and body composition analyses were performed. RESULTS: After 6 months, a significant reduction was observed in psoriasis area severity index (p < 0.001) from 18 to 0, in c-reactive protein (p < 0.001) from 6.6 to 4.00 mg/L, in low-density lipoprotein-cholesterol (p = 0.004) from 3.69 to 3.19 mmol/L, and an improvement in high-density lipoprotein-cholesterol (p = 0.022) from 1.31 to 1.40 mmol/L. Median baseline body mass index was 32.80 kg/m2. The body composition parameters did not show any significant changes. CONCLUSIONS: Anti-interleukin-17 therapy of severe psoriatic patients does not cause significant changes in body composition parameters. Improvements in the lipid and inflammatory parameters might have a beneficial effect on patients’ cardiometabolic status. This effect might be detectable in high-risk obese psoriatic patients.

28 October 2024 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PBPéter Bacsur 
Péter Bacsur 
DSDaniel Shaham
Daniel Shaham
ZSZuzana Serclova
Zuzana Serclova
TRTamás Resál
Tamás Resál
BFBernadett Farkas
Bernadett Farkas
TMTamás Molnár
Tamás Molnár
Background: Perianal fistulas of Crohn's disease (CD) create a significant burden on patients' lives. However, the efficacy and safety of adipose‐derived mesenchymal stem cell treatment are contradicting, and real‐world evidence is lacking.Aims: To examine the usability of darvadstrocel therapy in managing perianal CD.Methods: We enrolled patients with CD and perianal fistulas in this retrospective multicenter study. The primary outcome was perianal clinical remission (defined as all treated fistulas closed) at weeks 26 and 52. Secondary outcomes were clinical response rates (≥ 1 fistulas closed), perianal activity (PDAI), patient satisfaction, and adverse events. Data were recorded at baseline and weeks 12, 26 and 52. Prediction of primary outcomes was performed by logistic regression.Results: Overall, among 223 patients (male/female ratio: 0.48), perianal clinical remission was achieved in 78.2% and 62.3% until weeks 26 and 52. Baseline PDAI score (OR 0.75), number of fistulas (OR 0.28) and the number of weeks after preparation for surgery (OR 0.98) were associated with treatment failure. The clinical response rates were 84.8% and 79.8% at weeks 26 and 52. Improvement of subjective perianal symptoms was achieved in 77.8% and 78.4% of patients, respectively. Adverse events occurred in 13.5% of patients; perianal abscesses and proctalgia were the most frequently reported.Conclusion: Effectiveness data were higher than in clinical trials. The safety profile was reassuring, and patients' satisfaction was high. Appropriate patient selection, fistula preparation and expertise may help to achieve treatment success.

21 August 2008 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
TSTamas Szamosi
Tamas Szamosi
Peter L LakatosPeter L Lakatos
Peter L Lakatos
TGThe Hungarian IBD Study Group
The Hungarian IBD Study Group
ASAniko Szilvasi
Aniko Szilvasi
LLLaszlo Lakatos
Laszlo Lakatos
HAHajnalka Andrikovics
Hajnalka Andrikovics

1 May 2012 in Orvosi Hetilap
Verified
Journal Article
Open access
MJMárk Juhász
Márk Juhász
DKDorottya Kocsis
Dorottya Kocsis
TZTamás Zágoni
Tamás Zágoni
PMPál Miheller
Pál Miheller
LHLászló Herszényi
László Herszényi
ZTZsolt Tulassay
Zsolt Tulassay
Coeliac disease (gluten-sensitive enteropathy, sprue) is a chrocic disorder of the small bowel leading to malabsorption. Aims: charts of all patients with coeliac disease treated at the 2nd Department of Medicine, Semmelweis University were evaluated. Patients and Methods: The authors retrospectively analysed the results of a total of 132 patients with coeliac disease (107 females and 25 males; mean age, 37 years; median, 35 years; range, 19–78 years) atteding the centre between 1999 and 2010. The authors routinely performed the following investigations in patients with suspected coeliac disease: multiple biopsies taken from the duodenum, tissue transglutaminase antibody or endomysial antibody based serology, body mass index calculation, osteodensitometry, evaluation of disorders associated with coeliac disease, family history for coeliac disease, and implementation of family-screening for coeliac disease given the agreement of the index patients. Results: Histological samples were available in 101 cases, and distributions of data according to the Marsh-classification were as follows: negative in 9%, M3a in 27%, M3b in 18%, and M3c in 46% of cases, respectively. Serological results were available in 117 cases. 93/117 (79%) showed seropositivity. Body mass index was calculated for 95 patients, and the mean value for males was 22.4 kg/m² (range, 17–30.3 kg/m²), whereas the mean value for females was 20.7 kg/m² (range, 15.2–30.4 kg/m²). Osteodensitometry was performed in 90 patients; 45 patients (50%) proved normal, 31 (34%) had osteopenia, and 15 (26%) had osteoporosis. Coeliac disease associated disorders were present in 45/132 patients (34%; 6 males). Associated disorders were as follows: 15 dermatitis herpetiformis Duhring, 15 thyroid diseases (5 hypo- and 10 hyperthyroidism), 6 Crohn’s disease, 3 selective IgA-deficiency, 2 endometrioses, 1 systemic lupus erythematosus, 1 myasthenia gravis, and 1 type-1 diabetes mellitus. Sixty-four of the 132 index patients brought 133 first-degree relatives for family screening (serology), where 26/133 (19.5%; 17 females) first-degree relatives proved to suffer from coeliac disease. Conclusions: The age distribution of this cohort demonstrates that coeliac disease can present at any age. Similarly to those of other coeliac disease centres, female predominance is significant. Histology usually showed advanced villous atrophy. Serological results were usually in conjunction with the histological results and proved to be useful for monitoring dietary compliance and for accomplishing family screening. The mean body mass index values were in the normal range confirming that adult patients with coeliac disease are usually not malnourished. The 20% prevalence of coeliac disease among first-degree relatives underlines the necessity of family screening. Orv. Hetil., 2012, 153, 776–785.

4 March 2015 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
ÁCÁ. A. Csontos
Á. A. Csontos
AMA. Molnár
A. Molnár
PMP. Miheller
P. Miheller

1 April 2013 in Revista Española de Enfermedades Digestivas
Verified
Journal Article
Open access
PDF file
KLKatalin Lorinczy
Katalin Lorinczy
MJMárk Juhász
Márk Juhász
ÁCÁgnes Csontos
Ágnes Csontos
BFBálint Fekete
Bálint Fekete
OTOrsolya Terjék
Orsolya Terjék
TZTamás Zágoni
Tamás Zágoni
Coeliac disease (CD) and its cutaneous manifestation, dermatitis herpetiformis are both (DH) gluten-sensitive diseases. Metabolic bone disease is common among patients with CD, even in asymptomatic forms. Data are scarce about bone density in patients with dermatitis herpetiformis. The aim of our study was to compare bone mineral density (BMD) of celiac and dermatitis herpetiformis patients. 34 coeliac patients, 53 with dermatitis herpetiformis and 42 healthy controls were studied. The mean age was 38.0 +/- 12.1, 32.18 +/- 14.95, 35.33 +/- 10.41 years in CD, dermatitis herpetiformis, and healthy controls, respectively. Bone mineral density of the lumbar spine, the left femoral neck and radius were measured by dual-energy X-ray absorptiometry. Low bone density, osteopenia and osteoporosis were defined as a body mass density (BMD) T-score between 0 and -1, between -1 and -2.5, and under -2.5, respectively. at lumbar region, consisting of dominantly trabecular compartment, a decreased BMD was detected in 49 % (n = 26) patients with dermatitis herpetiformis, 62 % (n = 21) of CD patients, and 29 % (n = 12) of healthy controls, respectively. Lower BMD were measured at the lumbar region in dermatitis herpetiformis and CD compared to healthy subjects (0.993 +/- 0.136 g/cm2 and 0.880 +/- 0.155 g/cm2 vs. 1.056 +/- 0.126 g/cm2; p < 0.01). Density of bones consisting of dominantly cortical compartment (femoral neck) did not differ in dermatitis herpetiformis and healthy subjects. our results show that a low bone mass is also frequent among patients with dermatitis herpetiformis. Bone mineral content in these patients is significantly lower in those parts of the skeleton which contain more trabecular than cortical bone.